{
  "docId": "019de076-4b6e-745e-b621-2097373bdc12",
  "docSlug": "454a033dcd11e0912fc4b281c3c86d65",
  "documentTitle": "Innoviva | Results Presentation Deck | 7 slides",
  "authorId": "innoviva",
  "authorName": "Innoviva",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 2,
  "pageCount": 7,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Headline doubles as action title with a positive-result takeaway; body is a pure bulleted summary with footnoted Lancet citations and Innoviva branding bottom-right.",
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de076-4b6e-745e-b621-2097373bdc12/2",
  "deckHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12",
  "deckJsonHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12.json",
  "deckAnchorHref": "/decks/019de076-4b6e-745e-b621-2097373bdc12#slide-2",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.12,
        "x": 0.86,
        "y": 0.93
      },
      "kind": "image",
      "text": "INNOVIVA Specialty Therapeutics",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11ba28bd-fc97-4f67-b62a-bf8989f3307d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.74,
        "w": 0.9,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "list",
      "text": "An estimated 82 million patients contract gonorrhea each year, with rising resistance to standard of care. Global pivotal phase 3 trial with GARDP tested single 3g oral dose of zoliflodacin vs. ceftriaxone + azithromycin. Met primary efficacy endpoint, non-inferior (point estimate 5.3%, 95% CI: 1.4%-8.7%). Comparable cure at rectal/pharyngeal sites. Safe and well-tolerated, no discontinuations or deaths. Important therapeutic option and milestone vs. antimicrobial resistance.",
      "attrs": {
        "bullet_count": 6
      },
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ad1125d-30f0-441f-bfbd-4bad775ef736",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.04,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1 - WHO global antimicrobial resistance surveillance. Lancet Microbe 2021; 2: e627-36. 2 - Lancet 2023; 9: e332-33",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33dc7970-8a69-45ce-911b-e5eb751dcf67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Top line summary: positive zoliflodacin Phase 3 results",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "021b4246-0b22-49a6-8d38-aad99cd01d1f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "a5455769-f1c5-45b6-a1f8-40740c7d4216",
      "evidence": "The slide provides a top-line summary of the positive zoliflodacin Phase 3 results.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "Executive summary",
      "slug": null,
      "matchId": "0e889ec5-09f1-406f-b80f-22b233f72b61",
      "evidence": "Slide labeled 'Top line summary' presents six bullets distilling the entire Phase 3 readout (problem, study design, primary endpoint, secondary endpoints, safety, strategic significance).",
      "confidence": 0.9
    },
    {
      "name": "Pyramid Principle",
      "slug": null,
      "matchId": "031df056-0aa4-4e3f-9f07-9c702dd0a3af",
      "evidence": "Action-title headline states the conclusion ('positive Phase 3 results'); supporting bullets elaborate the underlying evidence.",
      "confidence": 0.65
    }
  ],
  "arcBeats": [
    {
      "to": 2,
      "from": 2,
      "beatId": "2dd973bd-2205-4a64-8b7e-91aa8f1ca8cd",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "Positive topline summary",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 2,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cc60ccb3-7bfb-482b-bd2f-71df33588aa9",
      "evidence": "Implication of antibiotic resistance and need for new treatments",
      "position": 0,
      "objective": "What are the consequences of not adopting Zoliflodacin?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}